Target intelligence / Profile preview

Aquaporin-7 (AQP7)

Target
AQP7
Molecular classification
Transporter, Aquaporin, Major intrinsic protein (MIP) family, Aquaglyceroporin (subclass of aquaporins selective for glycerol and small solutes)
01

Overview

Aquaporin-7 is a membrane transporter of the aquaporin family that primarily facilitates glycerol transport across the plasma membrane of adipocytes and other tissues such as testis, kidney, and muscle[1][2]. It enables the rapid, selective movement of glycerol, water, and urea, and is crucial for lipid and energy metabolism. The AQP7 channel's function is tightly regulated—hormonally controlled trafficking modulates its localization between lipid droplets and the plasma membrane in adipocytes, supporting the release of glycerol during lipolysis and influencing fat storage/mobilization dynamics[1]. AQP7 dysfunction or altered expression is linked to several metabolic diseases, notably obesity and diabetes, and is being investigated as a potential therapeutic target. Its unique structure includes areas devoted to both water and glycerol selectivity, distinguishing it from "orthodox" aquaporins, which transport exclusively water[1][2][3].

Other names
Aquaporin-7AQP7AQP-7AQPapAquaglyceroporin-7Aquaporin adiposeAquaporin-7-likeAQP7LGLYCQTL
02

Mechanism of action

Inhibitors or modulators would act by altering glycerol and/or water permeability across adipocyte and other cell membranes, potentially affecting adipose tissue metabolism and systemic lipid/glucose homeostasis[1].

03

Biological functions

Glycerol transportWater transportUrea transportLipid metabolism regulationThermoregulationSperm function
04

Disease associations

Metabolic disorders (including obesity and diabetes)Cardiovascular disease (via lipid metabolism and adipose tissue dysfunction)Potential involvement in male infertility
05

Safety considerations

Targeting AQP7 could disrupt whole-body glycerol and water homeostasis, potentially causing metabolic disturbances or dehydration[1].
06

Interacting drugs

Currently, there are no approved drugs directly targeting Aquaporin-7, but research is ongoing for small-molecule modulators[1].
07

Biomarkers

AQP7 expression or mutation status in adipose tissue may serve as a biomarker for metabolic syndrome, obesity, or diabetes risk; confirmed biomarkers for clinical use are not yet established[1].

Beyond the preview

Go deeper on Aquaporin-7 (AQP7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquaporin-7 (AQP7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call